Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154219
Status:
COMPLETED
Last Update Posted:
2012-05-21
First Post:
2005-09-07
Brief Title:
Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 13-week Multicenter Randomized Double-blind Double-dummy Placebo-controlled Parallel Group Trial of Lumiracoxib COX189 100 mg od in Patients With Primary Hip Osteoarthritis Using Celecoxib 200 mg od as a Positive Control
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy tolerability and safety of the investigational drug lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis Both lumiracoxib and celecoxib belong to the same class of drug COX-2 selective nonsteroidal anti-inflammatory drugs NSAIDs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None